Inhibikase Therapeutics, Inc.
SEC CIK 1750149 · IKT · last insider filing 2026-06-30
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Berman Dennis N | Director | filed 2020–2026 |
| Munshi Amit | Director | filed 2024–2026 |
| Vincent Aurentz | Director | filed 2025–2026 |
| Bellini Roberto | Director | filed 2024–2026 |
| Kush Arvind | Director | filed 2024–2026 |
| Canner David | Director | filed 2024–2026 |
| Iwicki Mark T | Director · Chief Executive Officer | filed 2025–2026 |
| Freeman Roy Lester | Director | filed 2020–2025 |
| Werner Milton H. | Director · President and CEO | filed 2020–2025 |
| Grint Paul C | Director | filed 2020–2024 |
| Dion Gisele | Director | filed 2022–2024 |
| O'Farrell Elizabeth G. | Director | filed 2020–2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Cabell Christopher | President & Head of R&D | filed 2025–2026 |
| Mcintyre David | Chief Financial Officer | filed 2025–2026 |
| Lees-Rolfe Garth | Chief Financial Officer | filed 2024–2025 |
| Frattaroli Joseph | Chief Financial Officer | filed 2020–2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.